Merck, AstraZeneca's sNDA for breast cancer treatment granted priority review by the FDA

Merck & Co. Inc. /zigman2/quotes/209956077/composite MRK -0.44% and AstraZeneca PLC /zigman2/quotes/200304487/composite AZN +0.34% said Tuesday that their supplemental New Drug Application (sNDA) for its breast cancer treatment Lynparza has been accepted and granted priority review by the U.S. Food and Drug Administration. Lynparza's sNDA is for the adjuvant treatment of patients with BRCA-mutated, human epidermal growth factor receptor 2-negative high-risk early breast cancer who have already been treated with chemotherapy. The sNDA was based on results from a Phase 3 trial that showed Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrence, second cancers or death by 42% versus placebo. Merck's stock slipped 0.2% in premarket trading, but outperformed the 1.2% drop in futures /zigman2/quotes/210407078/delayed YM00 +0.0092% for the Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA +0.40% ahead of the open.

/zigman2/quotes/209956077/composite

Add to watchlist MRK

Merck & Co. Inc.

US : U.S.: NYSE

$ 105.08

-0.46 -0.44%

Volume: 2.49M

March 22, 2023 2:43p

P/E Ratio

18.37

Dividend Yield

2.78%

Market Cap

$267.92 billion

Rev. per Employee

$847,435

/zigman2/quotes/200304487/composite

Add to watchlist AZN

AstraZeneca PLC ADR

US : U.S.: Nasdaq

$ 67.22

+0.23 +0.34%

Volume: 2.64M

March 22, 2023 2:42p

P/E Ratio

63.55

Dividend Yield

2.12%

Market Cap

$206.10 billion

Rev. per Employee

$531,150

/zigman2/quotes/210407078/delayed

Add to watchlist YM00

E-Mini Dow Continuous Contract

US : U.S.: CBOT

$ 32,777.00

+3.00 +0.0092%

Volume: 103,034

March 22, 2023 1:33p

/zigman2/quotes/210598065/realtime

Add to watchlist DJIA

Dow Jones Industrial Average

US : Dow Jones Global

32,691.68

+131.08 +0.40%

Volume: 0.00

March 22, 2023 2:43p